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Abstract
Background: Fatigue is increasingly recognized as an important symptom in fibromyalgia (FM). Unknown however
is how fatigue is experienced by individuals in the context of FM. We conducted qualitative research in order to
better understand aspects of fatigue that might be unique to FM as well as the impact it has on patients’ lives.
The data obtained informed the development of a conceptual model of fatigue in FM.
Methods: Open-ended interviews were conducted with 40 individuals with FM (US [n = 20], Germany [n = 10]
and France [n = 10]). Transcripts were analyzed using qualitative methods based upon grounded theory to identify
key themes and concepts.
Results: Participants were mostly female (70%) with a mean age of 48.7 years (range: 25-79). Thirty-one individuals (i.
e., 77.5%) spontaneously described experiencing tiredness/lack of energy/fatigue due to FM. Participants discussed
FM fatigue as being more severe, constant/persistent and unpredictable than normal tiredness. The conceptual
model depicts the key elements of fatigue in FM from a patient perspective. This includes: an overwhelming feeling
of tiredness (n = 17, 42.5%), not relieved by resting/sleeping (n = 15, 37.5%), not proportional to effort exerted
(n = 25, 62.5%), associated with a feeling of weakness/heaviness (n = 20, 50%), interferes with motivation (n = 22,
55%), interferes with desired activities (n = 27, 67.5%), prolongs tasks (n = 15, 37.5%), and makes it difficult to
concentrate (n = 21, 52.5%), think clearly (n = 12, 30%) or remember things (n = 9, 22.5%).
Conclusion: The majority of individuals with FM who participated in this study experience fatigue and describe it
as more severe than normal tiredness.
Background
Fibromyalgia (FM) is a chronic disorder characterised by
widespread pain and tenderness [1,2], with an estimated
prevalence in adults ranging from 0.5-10% worldwide
[3-9] with a predominance among females [10]. In addi-
tion to chronic widespread musculoskeletal pain, symp-
toms of fatigue, sleep disorders, headaches, memory or
concentration problems, mood disturbances, and stiff-
ness are also commonly associated with FM [1,2,4,11].
Previous focus groups found that, in addition to pain
and sleep disturbance, fatigue was perceived by patients
to be one of the three most bothersome symptoms of
FM [11]. A Delphi study by 23 FM expert clinicians
identified fatigue as being the second most important
domain to measure (after pain), and it was subsequently
rated as third most important (after pain and overall
FM) by a Delphi study involving patients [12]. At the
Outcome Measures in Rheumatology (OMERACT) 7
workshop composed of clinicians, researchers, regulatory
and industry representatives, 94% of participants agreed
that fatigue was an essential domain to measure in FM
clinical trials [13]. Thus, there is growing consensus
among patients, as well as clinical experts, that fatigue is
a key symptom to assess in clinical trials of FM. This is
further supported by other publications of qualitative
FM patient research [14-18].
Like pain, the measurement of fatigue relies on patient
report. Recent guidance from regulators highlights that
patient input (ideally in the form of qualitative research)
is critical when developing or selecting a patient-reported
outcome (PRO) measure for a specific condition [19,20].
Existing fatigue measures such as the Multidimensional
Fatigue Inventory (MFI) [21] and the Multidimensional
Assessment of Fatigue (MAF) have been used extensively
in FM clinical trials [22-27]. However, no existing
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and qualitative interviews with FM patients were not
included in the development of any existing fatigue mea-
sures. Thus, in-depth, qualitative research with FM
patients is needed that focuses on exploring the experi-
ence of fatigue in FM in order to provide an understand-
ing of how it can be best measured (which may be
through using existing instruments or through the devel-
opment of a new, FM-specific measure of fatigue).
The current project seeks to explore fatigue in detail
through in-depth, qualitative interviews with individuals
who have FM. The results will inform the development
of a conceptual model of fatigue in FM. The conceptual
model will define the properties of FM fatigue (and the
relationship between each concept and the symptom)
and will then be used to support the selection or devel-
opment of PROs for this symptom.
Methods
Sample and study design
Open-ended, qualitative interviews were conducted with
40 individuals with FM in the US (5 male, 15 female),
Germany (5 male, 5 female) and France (2 male, 8 female)
(Table 1). Participants were recruited through primary
care physicians/general practitioners, pain specialists and
rheumatology specialists and the sample included indivi-
duals from three different countries/cultures/languages to
increase the likelihood that findings could be generalized
across cultures/languages. Purposive sampling ensured the
inclusion of individuals from a range of educational back-
grounds and ethnicities [28]. In each country, a minimum
of 20% of participants were male, and a minimum of 30%
had an education level of high school (or equivalent) or
less. In the US, a minimum of 10% were non-Caucasian to
ensure ethnic diversity.
Inclusion/exclusion criteria
Participants were at least 18 years of age, met the Amer-
ican College of Rheumatology (ACR) criteria for FM (1)
and were willing and able to participate in a 90-minute
interview. Participants were excluded if they had signifi-
cant physical or psychiatric co-morbidities (including
severe pain not related to FM) that might have inter-
fered with their experience of, or ability to talk about,
FM. Of note, participants were not required to have fati-
gue - they were only required to have a diagnosis of FM
because this study was part of a larger project looking at
other FM domains in addition to fatigue.
Ethics
Ethics approval of the study protocol, documents and pro-
cedures was granted by Copernicus, a US centralized Inde-
pendent Review Board, and written informed consent was
obtained from all participants prior to entry into the study.
Interview methods
All interviews were conducted by an experienced quali-
tative interviewer, who was a native speaker of the lan-
guage in which the interview was performed. Using a
semi-structured interview guide, questions were initially
open-ended to ensure participants were not biased by
the topics of interest (e.g., “tell me about your experi-
ence of having fibromyalgia?”). Direct questioning was
only used when topics of importance did not arise in
response to the open-ended questions.
Participants were first asked to talk about their general
experience of FM and then asked to describe good and
bad days with FM. Participants were also asked what
three things bothered them most about having FM.
These exploratory questions were followed by two crea-
tive tasks that encouraged participants to talk in a spon-
taneous, more creative manner about their FM. First,
prior to interview, participants were asked to create a
drawing or collage representing their FM which was
discussed during the interview. In the second task, parti-
cipants were asked: “if your FM was an animal, what
animal would it be?” Participants were asked open ques-
tions about “FM” generally rather than fatigue specifi-
cally so that if fatigue was discussed, it was identified
spontaneously by the participant indicating the impor-
tance of the symptom to FM patients.
Only after these open-ended questions and creative
tasks did the interview progress to more focused ques-
tions relating to FM fatigue (if not already discussed).
This methodology gives participants the opportunity to
mention FM fatigue spontaneously and also to mention
concepts/symptoms/domains of importance which may
not have been in the discussion guide [29].
At the end of each interview, participants were asked
to list the symptoms of FM they experience and to rate
their pain, fatigue, cognition and functioning using
Visual Analogue Scales (VAS) and Numerical Rating
Scales (NRS). Each interview lasted approximately 90
minutes. Revising the guide was considered after the
first five interviews; no revisions were required.
Patient-reported questions and demographics
As well as completing the VAS and NRS symptom ques-
tions, participants also provided information regarding
their age, gender, number and age of children, living
situation (e.g. living alone, with a partner, etc), highest
level of education, work status and ethnicity. The
French participants were not asked for ethnicity as it is
considered culturally inappropriate.
Collection of clinician-reported information
To verify the patient-reported data and to provide addi-
tional clinical information, the recruiting physicians were
asked for background clinical information including: year
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co-morbidities. The clinicians chose which of a list of 20
‘symptoms and syndromes’ commonly associated with
FM (e.g. fatigue, stiffness, depression) were present in
their patient. There was also space for the clinician to
add any other symptoms/syndromes not listed.
Qualitative analysis
All interviews were audio-taped and transcribed verbatim
with any identifiable information removed during tran-
scription. Qualitative analysis of the verbatim transcripts
was conducted in the original language version of the tran-
script by an analyst who was also a native speaker. Coding
of quotes by concept/domain involved assigning appropri-
ate codes to patient statements determined by the under-
lying concept such as ‘difficulty remembering’ and then
grouping concepts into domains, for example, ‘cognitive
limitations’. This analysis approach is based on a
Grounded Theory approach [30-33] and Atlas Ti software
(Atlas.ti GmbH Berlin, Germany, version 5.2) was used.
The French and German transcripts were coded in both
their original language and their English translation
(to retain cultural meaning and identify any language
subtleties), and the developed code list compared with
codes from the US interviews to identify consistency in
the concepts emerging from the analysis. The coding
scheme, driven by the participants’ experience was devel-
oped iteratively, changed dynamically as more data was
analysed. The reliability of codes and definitions were con-
firmed through extensive discussion and consensus among
analysis team members. Codes were then organised into
higher order domains/concepts.
Saturation
Analysis was conducted to determine whether concep-
tual saturation was achieved. Saturation has been
defined as the point at which no new concepts or sub-
concepts emerge with the addition of more interviews
Table 1 Demographic characteristics of the sample.
Subject Characteristics US
(n = 20)
Germany
(n = 10)
France
(n = 10)
Total
(n = 40)
Age (years)
Mean 49.4 52.4 43.4 48.7
Median 50 51 41 49
Min, Max 25,69 46,58 30,58 25,69
Gender % (n)
Male 25 (5) 50 (5) 20 (2) 30 (12)
Female 75 (15) 50 (5) 80 (8) 70 (28)
Current Living status % (n)
Live alone 15 (3) 80 (8) 50 (5) 40 (16)
Live with husband/wife/partner 30 (6) 20 (2) 50 (5) 32.5 (13)
Live with parents/family or friends 45 (9) 0 0 22.5 (9)
Other 10 (2) 0 0 5 (2)
Ethnicity % (n)
Hispanic 0 (0) 0 N/A 0
Caucasian 80 (16) 90 (9) N/A 83.3 (25)
African American 10 (2) 0 N/A 6.7 (2)
Asian Oriental or Pacific Islander 0 (0) 0 N/A 0
Other 10 (2) 10 (1) N/A 6.7 (2)
Highest Education Level US and Germany % (n)
Secondary school education or less 20 (4) 20 (2) N/A 20 (6)
Vocational school or some college 30 (6) 40 (4) N/A 33.3 (10)
University/College degree 45 (9) 20 (2) N/A 36.7 (11)
Post-graduate degree qualification 5 (1) 20 (2) N/A 10 (3)
Highest Education Level France % (n)
Secondary school education or less N/A N/A 40 (4) 40 (4)
More than High School (France) N/A N/A 60 (6) 60 (6)
Do you currently work in a paid capacity (full or part-time) % (n)
Yes 65 (13) 20 (2) 30 (3) 45 (18)
No 35 (7) 80 (8) 70 (7) 55 (22)
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sample was examined by comparing the first 10 tran-
scripts with the next 10 to identify if any concepts aris-
ing in the second set of 10 interviews had not arisen in
the first 10 interviews. If new concepts had emerged,
additional interviews would have been conducted and
the saturation checking process repeated. For country-
level saturation, the concepts arising from the French
and German transcripts were compared to those arising
from the US interviews.
Results and Discussion
Background characteristics of the sample
Consistent with the samplingt a r g e t sa n dp r e v a l e n c eo f
FM [10], 28/40 participants (70%) were female, mean
age was 48.7 years (range: 25-69 years old) and patients
had a range of education levels. Of the 30 participants
who provided ethnicity information, the majority were
Caucasian (n = 25, 83%).
Clinician-reported background clinical data
Participants had been diagnosed with FM for a mean of
6.6 years (SD = 5.20, range = 1-18 years). The most
common clinician-reported FM-related “symptoms and
syndromes” were fatigue (n = 40, 100%), stiffness
(n = 39, 98%), sleep disorders (n = 37, 93%), joint aches
(n = 36, 90%) and tenderness to touch (n = 34, 85%).
Depression was identified in 37.5% (n = 15). Moreover,
depression was present among French (n = 7, 70%) and
US (n = 8, 40%) participants but was not reported for
any German participants. With the exception of depres-
sion, there were no patterns of particular symptoms/
syndromes being more frequently reported for any one
country sample. The majority of participants (n = 30,
75%) had no co-morbidities unrelated to FM.
Patient-reported questions
Mean scores for the quantitative patient-reported ques-
tions are presented in Figure 1. The total mean pain
severity score (rated on a VAS) was 5.97, with no major
differences among countries. The remaining PRO items
used a 0-10 NRS scale with 10 indicating greater diffi-
culty/severity. For all of the NRS items, the mean scores
were between 4 and 6 and there were no notable differ-
ences among the country samples for most items.
Qualitative interview findings: experience of fibromyalgia
When asked, “tell me about your experience of FM”,
pain was the most common spontaneously reported
concept (n = 31, 78%), followed by fatigue (n = 17,
43%), sleeping problems (n = 7, 18%) and mobility pro-
blems (n = 4, 10%). Participants were asked to state the
three things that bothered them the most about having
FM. Of the 35 who answered the question, 31 (89%)
mentioned pain. The second most commonly mentioned
concept was fatigue/tiredness/lack of energy mentioned
by 18/35 (51%) participants (11/17 in the US; 2/10 in
Germany; and 5/8 in France). The next most commonly
mentioned concept was functional limitations arising
from FM, mentioned by 9/35 (26%) participants.
Pain and tiredness/fatigue were the most common
concepts/themes described when participants discussed
their homework collages/drawings. Pain-related concepts
were mentioned by 18/40 (45%) participants who chose/
drew pictures of people in pain or indicated on their
collage an image that represented pain. Fatigue/tiredness
was mentioned by 10/40 (25%) - nine of whom were
from the US (and one from France). These participants
chose/drew pictures that depicted for example, people
sleeping, animals carrying heavy loads and characters
walking up steep hills. No German participants men-
tioned fatigue or tiredness in the spontaneous discussion
of their homework as they focused primarily on pain. In
the second creative task, participants had to think of an
animal that represented their FM and what their reasons
were behind their chosen animal. Of the 38 participants
who completed the task, 20 (53%) chose an animal that
related to fatigue/tiredness e.g. sloth or tortoise because
these animals were considered ‘slow’ or ‘lazy’. Fourteen
(37%) chose an animal that related to pain (e.g. porcu-
pine because of their spines, a lion because a roar sym-
bolized the pain they were in), and six (16%) chose an
animal related to the unpredictable and unpleasant nat-
ure of FM (e.g. snake ‘because you never know when it
is going to strike’). Of note, some participants chose
more than one animal (e.g. one to represent pain and
one to represent fatigue/tiredness) or also referenced
more than one concept when explaining their choice of
animal.
Qualitative interview findings: patient experience of
fibromyalgia fatigue
A conceptual model of FM fatigue was developed based
on the qualitative findings and on the previous qualita-
tive research that was reviewed [11,12,14,15] (Figure 2).
FM fatigue was described as an overwhelming feeling of
tiredness that was not relieved by sleep or rest and is
often not in proportion to the effort exerted (i.e. partici-
pants described becoming tired after doing very little).
Many described their fatigue as ‘feeling weak’ or their
body feeling heavy and almost all participants talked
about having to force themselves to do things or
described having difficulty getting motivated to do
things. Participants differentiated between FM fatigue
and normal tiredness by referring to the fact that FM
fatigue limited them in doing daily activities or caused
difficulty concentrating, thinking clearly and/or remem-
bering things. Detailed findings to support each of these
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ability to do day-to-day activities (n = 40).
Figure 2 Conceptual model of fibromyalgia fatigue.
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with sample participant quotes.
Overwhelming feeling of tiredness
Seventeen participants (43%) described how at times
they would become overwhelmed by their fatigue
(15 spontaneously and two when probed). Eight of these
participants (20% of the total sample) were, at times,
o v e r w h e l m e dt ot h ep o i n tt h a tt h e yw e r eu n a b l et od o
anything.
Not relieved by resting or sleeping
Fifteen participants (38%) described still experiencing
tiredness or fatigue, even after a good night’s sleep.
Not proportional to effort exerted
Twenty-five participants (63%) talked about becoming
tired very easily. For example, some individuals talked
about being exhausted after doing hardly anything.
Feeling of weakness or heaviness
Eleven participants (28%) talked about their body feeling
heavy, weak or not having any strength. Many of these
individuals felt so weak that it was difficult to do daily
activities.
Difficult to get motivated
Thirty-three participants (82.5%) talked about fatigue as
not having the motivation to do things or having to
force themselves to do things. Sixteen (40%) also
discussed the concept of motivation in relation to
having difficulty getting out of bed in the morning or
‘getting going’ in the morning. Others discussed the
amount of effort required to do things or of needing to
force themselves to do things.
Difficulty doing the things they want to do
The majority of participants (24/40, 60%) across all
three countries spontaneously talked about fatigue/tired-
ness making it difficult to do the things that they want
or need to do; one further individual talked about this
when probed. Activities affected by fatigue included
strenuous physical activities (e.g. playing sports, yard-
work), cognitive tasks (e.g. paying bills) and simple self-
care activities (e.g. pouring a cup of coffee, getting
dressed).
Having to do things more slowly
Fifteen participants (38%) talked specifically about hav-
ing to do things slowly, or taking longer to do things
due to tiredness or fatigue. In some cases this seemed to
be related to the feeling of heaviness or weakness.
Difficult to concentrate, think or remember things
Many participants (n = 27, 68%) talked about a mental
or cognitive component to their fatigue. Twenty-one
Table 2 Summary of the characteristics that define FM fatigue
FM-fatigue characteristics US
(n = 20)
France
(n = 10)
Germany
(n = 10)
Total
(n = 40)
Example Quote
Overwhelming feeling of
tiredness
10 4 3 17 “Feeling of just being, just overwhelmed by tired - just being tired and
sleepy and fatigued” - Female, aged 61, US
“you’re that tired, it’s this big oppressive - it’s like a blanket and it wraps
you up...it’s overwhelming” - Female, aged 33, US
Not relieved by resting or
sleeping
10 1 4 15 “I could sleep 20 hours and still be tired. That is terrible.” - Female, aged
58, Germany
“But when you sleep, it doesn’t resolve it. You still wake up tired. “ - Female,
aged 50, US
Not proportional to effort
exerted
17 4 4 25 “...whereas in this case you’ve done nothing, you shouldn’t feel tired, but
you do, you’re weary, completely lethargic.” - Female, aged 39, France
“In general, the fatigue, for me, it strikes quite bad, because I normally like
an active person. And now to do the simplest little thing, I can be where
I’m just totally worn out. Like I’ve been doing something all day long very
strenuous.” - Female, aged 49, US
Feeling of weakness or
heaviness
10 4 6 20 “your whole body feels really heavy, like I was saying about the cement suit
thing. I just feel like there’s a real heaviness to it.” -Female, aged 41, US
“I don’t shop, my friends do it for me, it is enough to go with them and
say what I want; that is exhausting enough. Exhaustion means that my
body feels lifeless and weak.” - Female, aged 50, Germany
Difficult to get motivated 12 5 5 20 “...you just don’t have the energy and the motivation to get out of the bed
and do anything” - Male, aged 50, US
“Yes, well, the lack of enthusiasm which I have, that I have to overcome to
motivate myself into doing something.” - Female, aged 58, Germany
Difficulty doing the things
they want to do
12 3 9 24 “...so you are too tired to go shopping, for example” - Male, aged 49,
Germany
Having to do things more
slowly
8431 5 “Because I’m sluggish no matter what I’m doing, that’s it! I need more time
doing things now that took me 5 minutes before!” - Female patient, aged
30, France
Difficult to concentrate, think
or remember things
12 7 8 27 “Well I think that the fatigue causes - I think it causes a lot of things to be
missing in a person’s concentration.” - Female, aged 56, US
“...you can’t think and you can’t hear, and everything’s grey.” - Female,
aged 33, US
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ing their ability to concentrate, nine (23%) talked about
difficulty remembering things, 12 (30%) talked about
having difficulties thinking clearly and eight (20%) men-
tioned having trouble staying focused. As examples of
activities affected by cognition problems some referred
to paperwork, others described having difficulty holding
simple conversations.
Terms used to refer to fatigue/tiredness/exhaustion
We were interested to know if participants distinguish
between “fatigue” that might result from FM and normal
tiredness. We were also interested to know if partici-
pants use the term “fatigue” to refer to something more
severe than normal tiredness. Throughout the inter-
views, participants spontaneously used many different
terms to describe their FM-related fatigue/tiredness.
Table 3 summarizes the terms participants used most
commonly to describe fatigue. At some point in the
interview almost all participants talked either of ‘feeling
tired’ (n = 27, 68%), being ‘fatigued’ (n = 14, 35%), hav-
ing ‘a lack of energy’/’no energy’/’little energy’ (n = 20,
50%) or feeling ‘exhausted’ (n = 13, 33%). Some talked
about feeling ‘worn out’ (n = 12, 30%) or ‘feeling weak’,
(n = 11, 28%); others talked about feeling ‘overwhelmed’
(n = 15, 38%) by their fatigue. In the French sample,
‘fatigué’ was used by all participants to refer to their
tiredness/fatigue. This term is usually translated as
meaning ‘tired’ or ‘tiredness’, but in some contexts
could also be translated as meaning ‘fatigue’ -w eh a v e
only translated it as meaning tired. Also of note, in Ger-
man there is a word that is typically translated as mean-
ing ‘tired/tiredness’ and another word translated as
‘exhausted’.H o w e v e r ,n ow o r dt h a tc o u l db ed i r e c t l y
translated as meaning ‘fatigue’,d i s t i n c tf r o mt h e s et w o
terms was referred to. In the German sample ‘tired’ was
by far the most common term.
Different participants often used the same term to
refer to different things; for example some participants
considered ‘energy’ to refer to the mental component of
fatigue, while others related ‘energy’ to the physical
component of fatigue. Furthermore, many participants
seemed to use the different terms interchangeably and
understood them all to be related to the same concept -
for example, when describing their tiredness participants
would often describe it as “al a c ko fe n e r g y ’. Neverthe-
less, whichever words participants used to talk about
their fatigue, all agreed it was worse than normal tired-
ness and referred to the characteristics in the model
presented in this study.
Qualitative interview findings: relationship between
fatigue and sleep problems
Almost all participants (n = 38, 95%) reported sleep pro-
blems due to their FM, most commonly because of pain.
Participants were asked whether or not the fatigue/tired-
ness they experienced was related to sleep problems.
Four concepts emerged: 1) the quality of sleep was
perceived by participants as impacting the severity of
fatigue the following day; 2) fatigue however, often
occurred irrespective of sleep quality; 3) difficulty sleep-
ing occurred irrespective of how tired a person was; and
4) some individuals experienced daytime sleepiness;
however most distinguished daytime sleepiness from
FM-fatigue/tiredness. These findings suggest that while
sleep problems and fatigue are related, the experience of
FM-fatigue was not perceived as being entirely explained
by the quantity or quality of sleep.
Qualitative interview findings: saturation analysis
In the US sample, saturation of all concepts was
achieved in the first 10 US interviews - no new concepts
or terms for talking about fatigue arose from the second
10 US interviews that had not arisen in the first 10
interviews. Country-level saturation was also attained
across the three samples - no new fatigue sub-concepts
emerged from the analysis of the French and German
transcripts that had not been mentioned in the US
interviews.
Qualitative interview findings: gender and country sub-
group analysis
Analysis of gender differences was conducted to exam-
ine the similarities/differences in the way men and
women talked about FM and their fatigue. Men and
women described the fatigue experience and its impact
in much the same way. There was some evidence that
men focused more on pain associated with their FM,
whereas women talked more about fatigue. Analysis of
any differences by country/language was also conducted;
although fatigue was frequently and spontaneously
reported in all three countries, US participants talked
the most about their fatigue, followed by the German
sample. French participants talked about fatigue the
least. However, all concepts included in the model were
mentioned by participants in all three countries, and
were clearly pertinent across all country samples. Parti-
cipants from all countries consistently talked about the
impact on daily activities or difficulties with concentra-
tion, thinking clearly and/or remembering things as
being delineating factors between FM fatigue and
“normal” tiredness.
In addition, the clinician-reported data showed that
more French and US patients experienced depression
than German patients. Although depression and fatigue
is strongly linked [35], our analysis revealed that there
were no sub-concepts of fatigue or FM impact that were
mentioned by only depressed patients. This suggests
that the concepts identified by participants in this study
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depression.
The primary objective of this research was to better
understand the patient experience of FM fatigue through
open-ended, qualitative research, as advocated by regula-
tors and experts in PRO development [19,36,37]. Find-
ings suggest that, while widespread pain is the primary
symptom of FM, fatigue appears to be the second most
important symptom and one that has a considerable
impact on patients’ lives. Although fatigue was not an
inclusion criterion in the present study, all participants
experienced fatigue. Fatigue was often one of the first
problems that participants mentioned when asked open-
ended questions. In some cases participants described
their fatigue as being worse than their pain because of
associated daily activity limitations. These findings are
consistent with, and build upon, previous exploratory
focus groups, which highlighted the importance of fatigue
Table 3 Summary of terminology used spontaneously to describe FM fatigue
Term US
(n = 20)
France
(n = 10)
Germany
(n = 10)
Total
(n = 40)
Example Quote
Tired/Tiredness 19 3 5 27 “Tired - tiredness is, I’m tired but I’m still going about my business, and
when I get extremely tired, I just know you have to stop and you need to
rest, lay down.” Female, aged 69, US
Tire easily 17 4 4 25 “This morning I got up and I was a little slow getting up and getting
moving. So I thought, OK, it’s going to be one of those days. But then I’m
sitting there, after my husband goes, OK, feeling better. And then the
tiredness came in. It’s like, no, you’re going to have to crash, that’s it.”
Female, aged 49, US
Tired upon waking 5229“And then okay... every day, every day... being tired when you wake up... I
say, “After all, you didn’t do anything excessive, nothing excessive, you...”
...I have a relatively healthy lifestyle... so.. I don’t see the why and how of
it...!” Male, aged 47, France
Sleepiness 5016Interviewer: “So, can you just describe that feeling, the tiredness feeling.”
Patient: “Sometimes it’s a sleepiness, as in sitting in my recliner on a bad
day, I’ll fall asleep.” Female, aged 49, US
No energy/Lack of
energy
1 6 042 0 “Just very tired, and just - really no energy, energy level very low.” Female,
aged 50, US
Fatigue
a 14 N/A N/A 14 “The fatigue, it’s number one, because I can deal with the pain, at least
up to a certain point, but the fatigue there’s nothing you can do besides
sleep. There is no way to help that. There’s no pill you can take, there’s
no medicine.” Female, aged 33, US
Feeling drained 6411 1 “Fatigue is just always just drained. Like feeling drained.” Female, aged 34,
US
Feeling weak 5241 1 “I feel like my body doesn’t have energy. Like I’m sitting here and the
effort that it would take for me to get up and walk, or run, I would think
about it before a normal person would, I think. I would think about the
energy it takes, and I would feel - I just feel like weighted down. That’s
what the fatigue feels like. It’s almost a weak feeling, or a heavy feeling.”
Female, aged 25, US
Exhausted/
exhaustion
8231 3 “I would feel tired, or exhausted, or just run down, those kind of terms,
which is all connected.” Female, aged 50, US
N o g e t u p a n d g o 5005“It feels like it’s like - like a plug has been pulled. The fatigue does, feels
like a plug has been pulled. And your get up and go, your energy has
just drained away. That’s the best I can describe it.” Male, aged 43, US
Shattered 0055“How can I describe it? I don’t have any energy, I don’t feel so tired that I
have to lie down but I am shattered. I have no desire to get up, I stay
sitting down and wait for the next burst of pain.” Male, aged 52, Germany
Worn out 1651 2 “And now to do the simplest little thing, I can be where I’m just totally
worn out. Like I’ve been doing something all day long very strenuous.”
Female, aged 49, US
Overwhelmed 8431 5 “When tiredness happens, there’s no relief. It’s like an overwhelming,
overarching, penetrating, consuming tiredness.” Female, aged 61, US
Tired even after
resting/good night’s
sleep
1 0 141 5 “But when you sleep, it doesn’t resolve it. You still wake up tired. So in
turn, it affects your motivation, because you have things that you want to
get done.” Female, aged 50, US
Emotional tiredness 1001“So there’s an emotional tiredness that comes with it. And I guess that
would be the difference.” Male, aged 43, US
a In French and German there is no term for fatigue that is distinct from the terms that are used for tiredness and exhaustion
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Page 8 of 10in FM [11]. In the focus groups, fatigue was described as
one of the worst symptoms of FM and was seen as a con-
stant presence that necessitated pacing the activities of
their lives. This theme is consistent with the findings in
the present research where participants reported having
to do things more slowly due to their fatigue. In an ear-
lier focus-group, participants also complained about a
lack of energy that accompanied an overwhelming feeling
of constant fatigue, consistent with this research. Thus,
the current research is consistent with the previous
research into FM fatigue [5,11,14-18] and provides strong
evidence that the majority of individuals with FM experi-
ence fatigue which has a substantial impact on daily
activities and wellbeing.
The finding that men seemed to focus more on pain,
whereas women talked more about fatigue, may indicate
that it is more socially acceptable for women to report
fatigue. Further investigation of this gender difference is
warranted. The reasons for thed i f f e r e n c e sb e t w e e nt h e
three countries in the frequency of fatigue being
reported are unclear, and caution must also be applied
in drawing conclusions from a small qualitative sample.
The differences could be due to: (1) country differences
in fatigue being a recognized symptom of FM; (2) lan-
guage differences (in German and French there is only
one word for both fatigue and tiredness - the absence of
a ‘clinical’ sounding word such as fatigue might make
patients more reluctant to report tiredness/fatigue); or
(3) cultural difference in willingness to report fatigue.
However, a significant proportion of the French and
German samples experienced fatigue, and the impact on
their lives was similar to that of the US patients. Quanti-
tative studies looking at these differences in reporting
fatigue are required to provide an understanding of
whether the gender and country differences reported
here are replicated in larger samples, or if they are an
artefact of this small, qualitative sample [5,38,39].
To build on this current work, it would be interesting
to compare the way FM patients talk about fatigue com-
pared to patients with other severe articular diseases (e.
g. rheumatoid arthritis), given that both groups of
patients report this symptom [40]. A comparative quali-
tative study with patients who have similar conditions
would be warranted to understand these differences and
generate a real conceptual view of the specificity of fati-
gue for these comparable conditions.
The qualitative findings reported here highlight the
challenges of developing a measure of fatigue that has
strong content validity. Thus, a possible solution to the
challenge of measuring FM fatigue might be to ask indi-
viduals about all of the different characteristics of fati-
gue outlined in the model, and to phrase the questions
using several of the different descriptors commonly used
by patients.
Conclusions
In conclusion, this study demonstrated that in addition
to pain, fatigue was an important symptom for indivi-
duals with FM. Individuals with FM used many terms to
talk about the concept of fatigue including ‘tired’, ‘fati-
gue’, ‘no energy’,a n df e e l i n g‘worn out’,o r‘exhausted’.
There was consensus among participants that FM-
related tiredness or lack of energy is worse than normal
tiredness. The conceptual model of FM fatigue captures
elements that distinguish FM fatigue from normal tired-
ness from a patient perspective. This conceptual model
is currently being used to support the development of a
new PRO for fibromyalgia fatigue.
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